In mammals, growth of the fetal heart is regulated by proliferation of cardiac muscle cells. At later stages of pre-natal life, this proliferation diminishes profoundly [1,2] and the dramatic expansion in heart size during the transition to adulthood is due exclusively to hypertrophy of individual cardiomyocytes [3] [4] [5] . Cardiomyocyte hypertrophy also contributes to the pathology of most post-natal heart disease [6-10]. Within this context, numerous signal transduction pathways have been implicated as the link between the effector(s) and altered cardiac gene expression [11] [12] [13] [14] [15] [16] . A common pathway has yet to be discovered, however. Here, we found that the activity of the stressactivated kinase p38 was enhanced in both types of cardiomyocyte hypertrophy. We also found that a target of the activated p38 kinase is the cardiac transcription factor MEF2. Transgenic mice expressing a dominant-negative form of MEF2C displayed attenuated post-natal growth of the myocardium. These results provide the first evidence for a single pathway regulating both normal and pathologic cardiomyocyte hypertrophy. 
Results and discussion
The stress-activated kinase p38 undergoes enhanced activation concurrent to the development of cardiomyocyte hypertrophy in a murine model of dystrophy, the mdx:MyoD -/-mouse [17] . Moreover, p38 activation leads to cardiomyocyte hypertrophy in vitro, suggesting an important role for this kinase in regulating post-natal growth of the myocardium [18, 19] . To discover the mechanism by which p38 induces cardiomyocyte hypertrophy, we identified protein targets of p38 during hypertrophic growth. Lysates from wild-type and mdx:MyoD -/-mice were subjected to co-immunoprecipitation with a p38 antibody followed by an in vitro kinase reaction. Although this assay labeled a number of targets, one protein migrating at approximately 53 kDa displayed an enhanced phosphate incorporation, which increased in mdx:MyoD -/-lysates ( Figure 1a ). To identify the 53 kDa protein, lysates were subjected to a pre-immunoprecipitation with antibodies to known p38 targets (including NFκB, MEF-2 and AP-1), followed by the same immunoprecipitation/kinase assay described above. Only the pre-immunoprecipitation with a MEF2 antibody resulted in a specific reduction in the phosphate labeling of the 53 kDa protein, which was similar to the reported size of MEF2 isoforms (Figure 1b,c) . In addition, mdx:MyoD -/-cardiac lysates subjected to MEF2 immunoprecipitation revealed an elevated association with p38 (as detected by western blotting), confirming the enhanced interaction of these proteins during hypertrophy (data not shown). MEF2 activity in heart lysates of wild-type and mdx:MyoD -/-mice. (a) The p38-directed phosphorylation of a 53 kDa protein, identified as MEF2 in a pre-immunoprecipitation (pre-IP) using an anti-MEF2 antibody. Asterisk, autophosphorylated form of p38. (b) Western blot with anti-p38 and anti-MEF2 antibodies. (c) Gel-shift assay using a labeled MEF2 consensus oligonucleotide. The total amount of protein used is indicated at the top. Specificity of the MEF2 complex (asterisk) was determined by competitive inhibition with unlabeled MEF2 consensus oligonucleotide (oligo) and supershifting of the complex with anti-MEF2 antibody (arrowhead). Similar results were obtained in three independent experiments. To examine MEF2 activity during cardiomyocyte hypertrophy, we performed gel mobility-shift assays using a MEF2-binding site as a probe. Compared with wild-type mice, heart lysates from mdx:MyoD -/-mice displayed a significant increase in MEF2 complex formation (Figure 1c) , which is similar to the enhanced MEF2 binding reported for pressure overload hypertrophy [20] . Consequently, these observations suggest a role for the activated kinase in pathologic cardiomyocyte hypertrophy. It is interesting that members of the MEF2 family of transcription factors, specifically MEF2A and MEF2C, have been shown to be indispensible for regulating cardiac gene expression, and are highly expressed in both the developing and mature myocardium ( Figure 1c ; reviewed in [21] ).
As normal post-natal cardiomyocyte growth exhibits many features common to disease hypertrophy, there may be considerable overlap in the molecular cascades that regulate each process. Accordingly, we investigated the interaction between p38 kinase and MEF2 transcription factors in the post-natal developing heart. Tyrosine phosphorylation of p38 was elevated in lysates derived from early-stage hearts and decreased in heart lysates of mature animals ( Figure 2a ). The heart lysates from the developmental time course were also subjected to p38 immunoprecipitation/kinase assays, which revealed a high level of MEF2 phosphate labeling (53 kDa protein) at early stages, declining with maturity ( Figure 2b ). In addition, gel mobility-shift assays demonstrated a high level of MEF2-binding activity for heart lysates derived from young mice (≤ 2 weeks of age), with a substantial reduction in activity as animals aged ( Figure 2d ). Therefore, upregulation of p38/MEF2 activity occurs at developmental stages when the heart is subject to the largest degree of cardiomyocyte hypertrophy. Interestingly, the elevated MEF2-binding activity was concurrent to an increased level of MEF2 proteins (Figure 2c ), suggesting a further synergy for p38-mediated activation of this transcription factor.
To determine whether increased p38/MEF2 activity was required for post-natal cardiomyocyte hypertrophy, we generated transgenic mice that expressed a truncated MEF2C protein (the carboxy-terminal transactivation domain was deleted) under the control of the α-myosin heavy chain promoter (α-MHC-MEF2C) [13, 22] . We hypothesized that removal of this region of MEF2C, which includes the known p38-regulatable serine and threonine residues [23, 24] , would result in a loss of functional protein. Indeed, similar truncations in MEF2A have been shown to produce a dominant-negative protein in vitro [25] . Cardiac lysates from MEF2 transgenic mice revealed a significant reduction in MEF2-DNA complex formation (Figure 3e ), which is similar to the dominant-negative effect that has been observed with overexpression of full-length MEF2C containing mutations in the p38-responsive residues [23] . Thus, our observations suggest that p38-mediated phosphorylation of MEF2 leads to an enhanced formation of MEF2-DNA complexes, which would directly affect MEF2-dependent transcription. Of the 11 independent founder mice that were obtained, three died early (≤ 4 weeks of age) with severe hypoplastic hearts ( Figure 3b and Table 1 ). Histological analysis of the affected hearts revealed a dramatic reduction in cardiomyocyte size compared with hearts from age-matched controls (Figure 3c,d) . Examination of hearts from surviving founder mice provided further support for a hypoplastic phenotype; two out of four mice had dilated ventricle chambers while maintaining outward cardiac dimensions similar to wild-type mice (data not shown). In addition, hearts from affected mice displayed a significant reduction (~2-3-fold) in the expression of genes associated with pathologic hypertrophy, such as Atrial natriuretic factor (ANF) (Figure 3f ) and α-skeletal actin (data not shown). Thus, disruption of MEF2 activity leads to impaired cardiomyocyte hypertrophy.
A simple interpretation of our observations suggests that p38 activation of MEF2 proteins in the hypertrophic heart may be specific to a p38-MEF2C interaction as, first, the p38 immunoprecipitation/kinase assays did not detect phosphorylation of a protein the size of MEF2A (~68-70 kDa) and, second, the competitive inhibition of the phosphorylated 53 kDa protein matched the known size of MEF2C (~53 kDa). Nevertheless, MEF2A protein, which is abundant in the adapting heart (Figure 2c ), has been shown to be a responsive target for p38-directed activation [24, 26] . Moreover, the cardiac phenotype of the MEF2C dominant-negative mouse does not exclude a role for MEF2A. Specifically, as MEF2A and MEF2C use a common consensus site, the underlying molecular basis for the dominant-negative MEF2C transgene would be equally effective in disrupting both MEF2C and MEF2A interactions with DNA.
Taken together, our data suggest that p38 activation of MEF2 is indispensible for precipitating the hypertrophic response in post-natal cardiomyocytes. Importantly, this interaction was evident in both normal and pathologic hypertrophy, which suggests a conserved molecular mechanism for cardiomyocyte adaptation. Finally, the data support the view that effective post-natal cardiac adaptation may be dependent on activating multiple cardiac transcription factors (that is, NFAT, GATA4 and MEF2), which recapitulates the paradigm observed for developmental cardiac morphogenesis [27] .
Materials and methods

Histological analysis
Hearts were removed and fixed in 4% paraformaldehyde for 4-5 days, embedded in paraffin, sectioned at 4 µm and stained with hematoxylin-eosin [28] .
Immunoprecipitation and western blot analysis
Immunoprecipitations and western blotting from the ventricle lysates were performed as described previously [17] . Briefly, for immunoprecipitations using the pan-tyrosine-phosphorylated antibody PY20 (Transduction Labs), 500 µg total protein was used with 5 µg PY20; for immunoprecipitations using anti-p38 (Santa Cruz) or anti-MEF-2 antibodies, 750 µg total protein was used with 2 µg of either anti-p38 or anti-MEF2 antibodies; all contained 25 µl protein G-Sepharose beads (Pharmacia). Immunoprecipitation was carried out for 16 h at 4°C. Precipitates were centrifuged, washed (3 ×) and subjected to SDS-PAGE followed by transfer to Immobilon-P membranes (Millipore). Detection of proteins by western blotting used the following dilutions for primary antibodies: p38 and MEF-2 1:500 (Santa Cruz); secondary 1:2000.
In vitro kinase assays
Immunoprecipitations with anti-p38 antibody were performed as described above. For MEF2 inhibition experiments, a pre-immunoprecipBrief Communication 1205 W i l d t y p e W i l d t y p e M u t a n t M u t a n t * Gel-shift assay C o n t r o l M u t a n t A M u t a n t B ANF northern -ANF itation (3 h at 4°C) with 2 µg anti-MEF2 antibody was performed before the p38 immunoprecipitation. Following this procedure, the precipitates were washed twice with kinase buffer [17] . Reactions were then carried out with 10 µCi [γ-32 P]ATP in a total kinase buffer volume of 30 µl.
Reactions were allowed to proceed for 30 min at 30°C and then terminated with the addition of 2 × SDS loading buffer and subjected to SDS-PAGE. Gels were dried and exposed to film and/or subjected to phosphoimaging to quantitate the signal.
Gel mobility-shift assays
Heart lysates were subjected to protein extraction as described above. Briefly, 200 µg total protein lysate per sample was incubated with a labeled ([γ-32 P]ATP) MEF2 consensus oligonucleotide probe (Santa Cruz) in the presence of 2 µg poly [dI-dC], 2 µl buffer (250 mM HEPES, pH 7.6, 50 mM MgCl 2 , 340 mM KCl) in a final volume of 20 µl for 30 min at 37°C, followed by gel electrophoresis. Competitor oligonucleotides were added at 50-fold molar excess, while supershift experiments were performed with 2 µg specific or non-specific antibodies. Signal quantification was determined by phosphorimager analysis.
Northern analysis
Total RNA extraction and northern blotting for ANF detection were performed as described previously [29] .
Transgenic mice
A MEF2C construct encoding amino acids 1-95 was produced by PCR amplification using primers corresponding to the required 5′ and 3′ regions. To direct post-natal cardiac-specific expression of the MEF2C construct, the sequence-verified PCR product was cloned into an expression vector containing the α-MHC promoter [22] . The fusion vector was then digested with BamHI, and the α-MHC-MEF2C transgene was gelpurified and eluted in oocyte injection buffer. Injection and derivation of transgenic mice were performed as described [30] .
